Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT

被引:0
|
作者
Gay, Hiram A. [1 ]
Liu, Jingxia [2 ]
Spencer, Christopher R. [1 ]
Lewis, James S., Jr. [3 ,4 ]
Diaz, Jason [4 ]
Nussenbaum, Brian [4 ]
Piccirillo, Jay F. [4 ]
Ferraro, Daniel J. [1 ]
Wildes, Tanya [5 ]
Sinha, Parul [4 ]
Adkins, Douglas R. [5 ]
Haughey, Bruce H. [4 ]
Thorstad, Wade L. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, 4921 Parkview Pl,Campus Box 8224, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Pathol & Immunol, St Louis, MO USA
[4] Washington Univ, Sch Med, Otolaryngol Head & Neck Surg, St Louis, MO USA
[5] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
关键词
p16+; Oropharynx squamous cell carcinoma; Adjuvant intensitymodulated radiation therapy; Transoral lasermicrosurgery; Human papillomavirus;
D O I
10.1007/s13566-014-0170-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives This study compares the outcomes of patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) treated with surgery followed by adjuvant radiotherapy (aRT) or chemoradiotherapy (aCRT). Methods From1997 to 2009, of 376 patients with OPSCC, 97 were p16+ and eligible: 51 received aRT and 46 received aCRT. Univariate and multivariate Cox regression, and propensity score analyses were performed. Results The 5-year locoregional failure (LRF) and distant metastases (DM) rates for the aRT and aCRT groups were 4 versus 0 % and 10 versus 9 %, respectively. The following were associated with a worse OS and DFS on multivariate analysis: pathologic T3/T4 stage (OS p=0.03; DFS p=0.02), age =55 years (OS p=0.02; DFS p=0.01), and a smoking history (OS p=0.02; DFS p=0.04). In multivariate and propensity score analyses, aCRT did not have a significant effect on OS, DFS, and DMFS. Conclusions In this retrospective study of postoperative p16+, stage III-IVb OPSCC patients receiving aRT or aCRT, we did not find a benefit in OS, DFS, or DMFS with the addition of chemotherapy to IMRT. Given the predominantDMfailure pattern in this surgical series, novel systemic strategies are needed. These data warrant further study.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [41] Human papillomavirus detection in oropharyngeal squamous cell carcinoma using p16 immunohistochemistry
    Sabu, Annetmary
    Mouli, N. V. Ratna
    Tejaswini, N.
    Rohit, V.
    Nishitha, G.
    Uppala, Divya
    [J]. INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2019, 9 (04) : 212 - 216
  • [42] RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma
    Berdugo, Jeremie
    Rooper, Lisa M.
    Chiosea, Simion I.
    [J]. HEAD & NECK PATHOLOGY, 2021, 15 (04): : 1109 - 1118
  • [43] p16 Immunohistochemistry As a Standalone Test for Risk Stratification in Oropharyngeal Squamous Cell Carcinoma
    James S. Lewis
    [J]. Head and Neck Pathology, 2012, 6 (Suppl 1) : 75 - 82
  • [44] RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma
    Jérémie Berdugo
    Lisa M. Rooper
    Simion I. Chiosea
    [J]. Head and Neck Pathology, 2021, 15 : 1109 - 1118
  • [45] HPV, p16, and bcl-2 expression in oropharyngeal squamous cell carcinoma
    Zapata, M.
    Muller, S.
    [J]. LABORATORY INVESTIGATION, 2007, 87 : 231A - 231A
  • [46] p16 Immunohistochemistry As a Standalone Test for Risk Stratification in Oropharyngeal Squamous Cell Carcinoma
    Lewis, James S., Jr.
    [J]. HEAD & NECK PATHOLOGY, 2012, 6 (01): : S75 - S82
  • [47] Is there justification for age bias in HPV p16 testing for Oropharyngeal Squamous Cell Carcinoma?
    McCauley, S.
    McCloskey, P.
    Lyons, C.
    Brown, K.
    Rooney, K.
    Houghton, F.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 122 : 50 - 51
  • [48] HPV, p16, and bcl-2 expression in oropharyngeal squamous cell carcinoma
    Zapata, M.
    Muller, S.
    [J]. MODERN PATHOLOGY, 2007, 20 : 231A - 231A
  • [49] Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining A Validation by Clinical Outcomes
    Barasch, Samuel
    Mohindra, Pranshu
    Hennrick, Kenneth
    Hartig, Gregory K.
    Harari, Paul M.
    Yang, David T.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (09) : 1261 - 1269
  • [50] Impact of delayed adjuvant therapy after surgery in p16 positive oropharyngeal cancer: a retrospective analysis
    Sievert, M.
    Goncalves, M.
    Mueller, S. K.
    Hecht, M.
    Pflaum, A.
    Grundtner, P.
    Iro, H.
    Gostian, A-O
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (03) : 1211 - 1218